Section 1307.41 - [Effective 1/1/2025] [Effective until 12/31/2025] Temporary extension of certain COVID-19 telemedicine flexibilities for prescription of controlled medications(a) This section is in effect until the end of the day December 31, 2025. The authorization granted in paragraph (b) of this section expires at the end of December 31, 2025.(b) During the period May 12, 2023, through December 31, 2025, a DEA-registered practitioner is authorized to prescribe schedule II-V controlled substances via telemedicine, as defined in 21 CFR 1300.04(i) , to a patient without having conducted an in-person medical evaluation of the patient if all of the conditions listed in paragraph (c) of this section are met.(c) A practitioner is only authorized to issue prescriptions for controlled substances pursuant to paragraph (b) of this section if all of the following conditions are met: (1) The prescription is issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice;(2) The prescription is issued pursuant to a communication between a practitioner and a patient using an interactive telecommunications system referred to in 42 CFR 410.78(a)(3) ;(3) The practitioner is: (i) Authorized under their registration under 21 CFR 1301.13(e)(1)(iv) to prescribe the basic class of controlled substance specified on the prescription; or(ii) Exempt from obtaining a registration to dispense controlled substances under 21 U.S.C. 822(d) ; and(4) The prescription is consistent with all other requirements of 21 CFR part 1306. 88 FR 30042 , May 10, 2023, as amended at 88 FR 69882 , Oct. 10, 2023 88 FR 69882 , 11/11/2023 through 12/31/2024; 89 FR 91257 , 1/1/2025 through 12/31/2025 As of November 11, 2023, the end of the effective period for the temporary rule published at 88 FR 30037 on May 10, 2023, is extended from November 11, 2024, to December 31, 2024. This rule is effective November 11, 2023.